Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1.

Mice Humans Animals Neuropeptide Y Receptors, Neuropeptide Y Angiotensin-Converting Enzyme Inhibitors / pharmacology Neprilysin Angiotensin Receptor Antagonists Hypertension, Portal / drug therapy Fibrosis Liver Cirrhosis / drug therapy
CP: Cell biology cirrhosis hepatic stellate cell neprilysin neuropeptide Y neuropeptide Y receptor 1 portal hypertension renin-angiotensin system

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 02 2023
Historique:
received: 23 07 2022
revised: 17 11 2022
accepted: 18 01 2023
medline: 4 10 2023
pubmed: 3 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Development of liver fibrosis is paralleled by contraction of hepatic stellate cells (HSCs), the main profibrotic hepatic cells. Yet, little is known about the interplay of neprilysin (NEP) and its substrate neuropeptide Y (NPY), a potent enhancer of contraction, in liver fibrosis. We demonstrate that HSCs are the source of NEP. Importantly, NPY originates majorly from the splanchnic region and is cleaved by NEP in order to terminate contraction. Interestingly, NEP deficiency (Nep

Identifiants

DOI: 10.1016/j.celrep.2023.112059 PMID: 36729833 PMC: PMC9989826
pubmed: 36729833
pii: S2211-1247(23)00070-0
doi: 10.1016/j.celrep.2023.112059
pmc: PMC9989826
pii:
doi:

Substances chimiques

Neuropeptide Y 0
Receptors, Neuropeptide Y 0
Angiotensin-Converting Enzyme Inhibitors 0
Neprilysin EC 3.4.24.11
Angiotensin Receptor Antagonists 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112059

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors have no conflict of interest.

Auteurs

Cristina Ortiz (C)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Sabine Klein (S)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany; Department of Internal Medicine B, University of Münster, Albert-Schweitzer Campus 1, 48149 Münster, Germany.

Winfried H Reul (WH)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Fernando Magdaleno (F)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Stefanie Gröschl (S)

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

Peter Dietrich (P)

Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.

Robert Schierwagen (R)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Frank E Uschner (FE)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Sandra Torres (S)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Christoph Hieber (C)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Caroline Meier (C)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Nico Kraus (N)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Olaf Tyc (O)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Maximilian Brol (M)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Stefan Zeuzem (S)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Christoph Welsch (C)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.

Marco Poglitsch (M)

Attoquant Diagnostics GmbH, Vienna, Austria.

Claus Hellerbrand (C)

Institute of Biochemistry, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Mercedes Alfonso-Prieto (M)

Institute for Neuroscience and Medicine INM-9 and Institute for Advanced Simulations IAS-5, Forschungszentrum Jülich, Jülich, Germany; Cécile and Oskar Vogt Institute for Brain Research, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Fabio Mira (F)

Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.

Ulrich Auf dem Keller (UAD)

Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.

Anja Tetzner (A)

Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.

Andrew Moore (A)

Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.

Thomas Walther (T)

Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland; Department of Pediatric Surgery, Centre for Fetal Medicine, Division of Women and Child Health, University of Leipzig, Leipzig, Germany; Department of Obstetrics, Centre for Fetal Medicine, Division of Women and Child Health, University of Leipzig, Leipzig, Germany.

Jonel Trebicka (J)

Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany; Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense, Denmark; European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain; Institute for Bioengineering of Catalonia, Barcelona, Spain; Department of Internal Medicine B, University of Münster, Albert-Schweitzer Campus 1, 48149 Münster, Germany. Electronic address: jonel.trebicka@ukmuenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Eucaryotes › Animaux › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Neuropeptides › Neuropeptide Y › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur aux neuropeptides › Récepteur neuropeptide Y › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéases › Inhibiteurs de l'enzyme de conversion de l'angiotensine › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Néprilysine › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antagonistes des récepteurs aux angiotensines › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Hypertension portale › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Neprilysin-dependent neuropeptide Y cleavage...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Neprilysin-dependent neuropeptide Y cleavage...